What is Senti Biosciences' operating income?

Senti Biosciences' total operating income in 2025 was -$68.78 million, based on the following breakdown: Total Gross Profit: $22 thousand Total Operating Expenses: $68.80 million

Senti Biosciences (SNTI) Financials

$0.44 -0.02 (-4.94%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$0.44 +0.01 (+1.37%)

As of 07/17/2026 07:52 PM Eastern

Compare

Annual Income Statements for Senti Biosciences

This table shows Senti Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-55	-58	-71	-53	-61
Consolidated Net Income / (Loss)	-55	-58	-71	-53	-61
Net Income / (Loss) Continuing Operations	-55	-50	-83	-53	-62
Total Pre-Tax Income	-55	-50	-83	-53	-62
Total Operating Income	-40	-62	-93	-61	-69
Total Gross Profit	2.76	4.29	2.56	0.00	0.02
Total Revenue	2.76	4.29	2.56	0.00	0.02
Operating Revenue	2.76	4.29	2.56	0.00	0.02
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	43	66	95	61	69
Selling, General & Admin Expense	21	38	37	26	26
Research & Development Expense	22	28	32	34	38
Impairment Charge	0.02	0.00	26	0.31	5.05
Total Other Income / (Expense), net	-15	12	9.32	8.30	7.15
Interest & Investment Income	0.01	1.70	2.86	0.95	0.93
Other Income / (Expense), net	-15	9.43	6.46	7.35	6.22
Basic Earnings per Share	($19.00)	($2.23)	($16.01)	($12.03)	($2.73)
Weighted Average Basic Shares Outstanding	2.91M	26.11M	4.44M	4.60M	22.48M
Diluted Earnings per Share	($19.00)	($2.23)	($16.01)	($12.03)	($2.73)
Weighted Average Diluted Shares Outstanding	2.91M	26.11M	4.44M	4.60M	22.48M
Weighted Average Basic & Diluted Shares Outstanding	-	44.17M	45.76M	26.00M	31.14M

This table shows Senti Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-15	-19	-12	-11	-29	-0.61	-14	-15	-18	-14	-4.22
Consolidated Net Income / (Loss)	-15	-19	-12	-11	-29	-0.61	-14	-15	-18	-14	-4.22
Net Income / (Loss) Continuing Operations	-37	-19	-12	-11	-29	-0.61	-14	-15	-18	-15	-4.24
Total Pre-Tax Income	-37	-19	-12	-11	-29	-0.61	-14	-15	-18	-15	-4.24
Total Operating Income	-44	-19	-16	-13	-15	-16	-16	-17	-17	-19	-4.62
Total Gross Profit	0.34	-	0.00	0.00	0.00	-	0.00	0.00	0.00	0.02	0.02
Total Revenue	0.34	-	0.00	0.00	0.00	-	0.00	0.00	0.00	0.02	0.02
Operating Revenue	0.34	-	-	-	-	-	0.00	-	-	-	0.02
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	44	19	16	13	15	16	16	17	17	19	4.63
Selling, General & Admin Expense	9.43	9.31	7.52	4.21	6.56	8.40	7.12	6.77	6.43	5.85	6.23
Research & Development Expense	9.09	9.12	8.78	9.15	8.66	7.77	9.28	10	11	7.76	5.28
Other Operating Expenses / (Income)	-	-	-	-	-	-	0.00	-	-	-	-6.88
Total Other Income / (Expense), net	7.26	0.01	4.19	2.15	-14	16	2.49	2.07	-1.18	3.98	0.38
Interest & Investment Income	0.58	0.43	0.33	0.24	0.15	0.23	0.39	0.27	0.17	0.10	0.10
Other Income / (Expense), net	6.68	-0.42	3.86	1.92	-14	15	2.09	1.80	-1.34	3.88	0.28
Basic Earnings per Share	($3.36)	($4.22)	($2.65)	($2.45)	($6.31)	($0.13)	($1.41)	($0.56)	($0.69)	($0.64)	($0.14)
Weighted Average Basic Shares Outstanding	4.45M	4.44M	4.57M	4.57M	4.58M	4.60M	10.01M	26.08M	26.23M	22.48M	30.97M
Diluted Earnings per Share	($3.36)	($4.22)	($2.65)	($2.45)	($6.31)	($0.13)	($1.41)	($0.56)	($0.69)	($0.64)	($0.14)
Weighted Average Diluted Shares Outstanding	4.45M	4.44M	4.57M	4.57M	4.58M	4.60M	10.01M	26.08M	26.23M	22.48M	30.97M
Weighted Average Basic & Diluted Shares Outstanding	44.55M	45.76M	45.76M	4.58M	4.59M	26.00M	26.08M	26.16M	26.29M	31.14M	31.14M

This table details how cash moves in and out of Senti Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	28	1.70	-22	12	-32
Net Cash From Operating Activities	-35	-35	-52	-41	-43
Net Cash From Continuing Operating Activities	-35	-35	-52	-42	-43
Net Income / (Loss) Continuing Operations	-55	-58	-71	-53	-61
Consolidated Net Income / (Loss)	-55	-58	-71	-53	-61
Depreciation Expense	0.77	1.40	3.56	3.84	3.64
Non-Cash Adjustments To Reconcile Net Income	1.18	29	10	13	8.40
Changes in Operating Assets and Liabilities, net	16	-9.68	4.01	-5.37	5.95
Net Cash From Investing Activities	-5.54	-82	30	0.03	-0.18
Net Cash From Continuing Investing Activities	-5.54	-82	30	0.03	-0.18
Purchase of Property, Plant & Equipment	-5.54	-41	-12	-0.03	-0.20
Sale of Property, Plant & Equipment	-	0.00	0.11	0.06	0.01
Net Cash From Financing Activities	68	119	0.78	54	12
Net Cash From Continuing Financing Activities	68	119	0.78	54	12
Repurchase of Common Equity	-	-	0.00	-0.23	-2.47
Issuance of Common Equity	0.00	0.88	0.89	49	11
Other Financing Activities, net	1.48	112	-0.11	4.90	3.05

This table details how cash moves in and out of Senti Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	5.74	-6.38	-12	-8.35	-5.37	38	-14	-12	-9.32	4.17	-7.49
Net Cash From Operating Activities	-15	-7.04	-12	-8.35	-7.87	-14	-14	-13	-9.45	-6.88	-7.48
Net Cash From Continuing Operating Activities	-15	-7.04	-12	-8.35	-7.87	-14	-14	-13	-9.45	-6.88	-7.48
Net Income / (Loss) Continuing Operations	-15	-19	-12	-11	-29	-0.61	-14	-15	-18	-14	-4.22
Consolidated Net Income / (Loss)	-15	-19	-12	-11	-29	-0.61	-14	-15	-18	-14	-4.22
Depreciation Expense	1.35	0.99	0.98	0.97	0.95	0.94	0.93	0.91	0.90	0.89	0.69
Non-Cash Adjustments To Reconcile Net Income	-2.48	4.54	-1.61	-1.52	16	-0.57	0.65	0.95	0.94	5.85	-4.81
Changes in Operating Assets and Liabilities, net	0.32	5.67	1.05	3.40	4.11	-14	-1.52	-0.21	6.83	0.85	0.86
Net Cash From Investing Activities	21	0.10	-0.02	-	0.06	-0.01	0.00	-0.18	-	-	0.11
Net Cash From Continuing Investing Activities	21	0.10	-0.02	-	0.06	-0.01	0.00	-0.18	-	-	0.11
Sale of Property, Plant & Equipment	-	0.11	-	-	0.06	-	0.00	-	-	-	0.11
Net Cash From Financing Activities	-0.02	0.56	0.00	-	2.44	51	-0.41	1.01	0.12	11	-0.12
Net Cash From Continuing Financing Activities	-0.02	0.56	0.00	-	2.43	51	-0.41	1.01	0.12	11	-0.12
Repurchase of Common Equity	-	-	0.00	-	-	-	-1.92	-0.53	-0.01	-	0.00
Other Financing Activities, net	-0.02	-0.02	0.00	-	2.43	2.47	1.51	1.01	-	0.53	-0.12

This table presents Senti Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	97	181	119	98	51
Total Current Assets	60	103	71	59	23
Cash & Equivalents	56	58	36	48	16
Accounts Receivable	0.48	0.63	18	1.81	1.60
Prepaid Expenses	3.68	3.18	18	8.88	5.26
Plant, Property, & Equipment, net	12	51	25	21	13
Total Noncurrent Assets	24	27	23	18	15
Other Noncurrent Operating Assets	24	22	22	18	15
Total Liabilities & Shareholders' Equity	97	181	119	98	51
Total Liabilities	36	54	53	47	46
Total Current Liabilities	15	18	13	13	14
Accounts Payable	11	14	7.18	7.84	8.30
Current Deferred Revenue	1.66	0.80	0.99	0.66	0.35
Other Current Liabilities	2.37	2.12	4.26	4.65	5.33
Total Noncurrent Liabilities	22	35	40	34	32
Other Noncurrent Operating Liabilities	22	35	40	34	32
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-111	127	67	26	5.59
Total Preferred & Common Equity	-111	127	67	26	5.59
Total Common Equity	-111	127	67	26	5.59
Common Stock	3.62	301	311	323	364
Retained Earnings	-115	-173	-244	-297	-359

This table presents Senti Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	132	102	87	58	83	69	53	38
Total Current Assets	79	56	44	17	45	33	18	15
Cash & Equivalents	39	24	16	10	34	22	12	8.94
Accounts Receivable	19	18	19	1.19	2.22	3.69	1.74	0.77
Prepaid Expenses	21	14	9.82	5.72	9.19	7.25	4.17	5.09
Plant, Property, & Equipment, net	26	24	23	22	21	20	19	12
Total Noncurrent Assets	26	22	19	18	17	16	16	11
Other Noncurrent Operating Assets	25	22	19	18	17	16	16	11
Total Liabilities & Shareholders' Equity	132	102	87	58	83	69	53	38
Total Liabilities	49	46	43	42	45	44	45	36
Total Current Liabilities	10	9.61	9.07	9.06	11	9.99	12	14
Accounts Payable	6.03	4.36	3.74	3.77	5.40	4.65	6.87	6.08
Current Deferred Revenue	1.05	0.86	0.80	0.64	0.51	0.36	0.00	2.30
Other Current Liabilities	2.82	4.39	4.51	4.63	4.81	4.98	5.15	5.89
Total Noncurrent Liabilities	39	36	34	33	34	34	33	21
Other Noncurrent Operating Liabilities	39	36	34	33	34	34	33	21
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	83	56	44	16	38	25	8.12	2.57
Total Preferred & Common Equity	83	56	44	16	38	25	8.12	2.57
Total Common Equity	83	56	44	16	38	25	8.12	2.57
Common Stock	309	313	312	313	349	351	352	365
Retained Earnings	-226	-256	-268	-297	-311	-326	-344	-363

This table displays calculated financial ratios and metrics derived from Senti Biosciences' official financial filings.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	58,931,000.00	43,857,077.00	44,545,186.00	-	26,290,838.00
DEI Adjusted Shares Outstanding	5,893,100.00	4,385,708.00	4,454,519.00	-	26,290,838.00
DEI Earnings Per Adjusted Shares Outstanding	-9.39	-13.27	-15.95	-	-2.34
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	55.23%	-40.25%	-100.00%	0.00%
EBITDA Growth	0.00%	6.13%	-66.85%	41.54%	-18.19%
EBIT Growth	0.00%	4.80%	-63.84%	37.71%	-16.51%
NOPAT Growth	0.00%	-53.50%	-49.36%	34.17%	-12.68%
Net Income Growth	0.00%	-5.23%	-22.07%	25.71%	-16.38%
EPS Growth	0.00%	88.26%	-22.07%	24.86%	77.31%
Operating Cash Flow Growth	0.00%	-0.75%	-50.15%	20.99%	-4.94%
Free Cash Flow Firm Growth	0.00%	0.00%	-11.31%	80.39%	-149.27%
Invested Capital Growth	0.00%	473.26%	25.47%	-92.07%	-537.09%
Revenue Q/Q Growth	0.00%	0.00%	-2.21%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	-6.64%	27.60%	-31.04%
EBIT Q/Q Growth	0.00%	0.00%	-7.45%	25.38%	-28.60%
NOPAT Q/Q Growth	0.00%	0.00%	-5.57%	3.98%	-3.72%
Net Income Q/Q Growth	0.00%	0.00%	-0.72%	25.54%	-29.12%
EPS Q/Q Growth	0.00%	0.00%	-0.72%	22.34%	-50.83%
Operating Cash Flow Q/Q Growth	0.00%	7.83%	3.62%	-18.51%	13.24%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-122.26%	5.23%
Invested Capital Q/Q Growth	0.00%	0.00%	-28.61%	-55.23%	-162.76%
Profitability Metrics	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	0.00%	100.00%
EBITDA Margin	-1,894.17%	-1,145.38%	-3,198.36%	0.00%	-267,813.64%
Operating Margin	-1,464.90%	-1,448.53%	-3,620.73%	0.00%	-312,631.82%
EBIT Margin	-2,003.19%	-1,228.53%	-3,368.61%	0.00%	-284,345.45%
Profit (Net Income) Margin	-2,003.59%	-1,358.14%	-2,774.62%	0.00%	-279,263.64%
Tax Burden Percent	100.04%	117.21%	85.20%	100.00%	99.69%
Interest Burden Percent	99.98%	94.32%	96.68%	98.24%	98.52%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-652.05%	-297.33%	-231.32%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-603.86%	-278.70%	-222.41%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	560.43%	235.28%	158.13%	0.00%	0.00%
Return on Equity (ROE)	-91.62%	-62.04%	-73.19%	-89.73%	-218.08%
Cash Return on Invested Capital (CROIC)	0.00%	-437.91%	-253.91%	-82.92%	0.00%
Operating Return on Assets (OROA)	-57.19%	-37.95%	-57.46%	0.00%	-83.93%
Return on Assets (ROA)	-57.21%	-41.95%	-47.33%	0.00%	-82.43%
Return on Common Equity (ROCE)	169.14%	-5.23%	-73.19%	-70.58%	-120.91%
Return on Equity Simple (ROE_SIMPLE)	49.63%	-45.74%	-106.19%	-205.82%	0.00%
Net Operating Profit after Tax (NOPAT)	-28	-43	-65	-43	-48
NOPAT Margin	-1,025.43%	-1,013.97%	-2,534.51%	0.00%	-218,842.27%
Net Nonoperating Expense Percent (NNEP)	-48.20%	-18.62%	-8.91%	-23.97%	-41.09%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-97.00%	-166.58%	-861.43%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	769.65%	891.86%	1,451.62%	0.00%	118,922.73%
R&D to Revenue	795.26%	656.67%	1,255.37%	0.00%	170,845.45%
Operating Expenses to Revenue	1,564.90%	1,548.53%	3,720.73%	0.00%	312,731.82%
Earnings before Interest and Taxes (EBIT)	-55	-53	-86	-54	-63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-52	-49	-82	-48	-59
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.49	0.44	0.63	4.89
Price to Tangible Book Value (P/TBV)	0.00	0.49	0.44	0.63	4.89
Price to Revenue (P/Rev)	0.00	14.43	11.48	0.00	1,242.84
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	496.48
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.93	-0.84	-0.71	-0.71	-1.15
Leverage Ratio	1.60	1.48	1.55	1.85	2.65
Compound Leverage Factor	1.60	1.39	1.50	1.81	2.61
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	284.60%	0.00%	0.00%	49.47%	0.00%
Common Equity to Total Capital	-184.60%	100.00%	100.00%	50.53%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	-1.03	-4.30	-5.30	-13.25
Noncontrolling Interest Sharing Ratio	284.60%	91.58%	0.00%	21.34%	44.56%
Liquidity Ratios	-	-	-	-	-
Current Ratio	4.14	5.68	5.62	4.49	1.67
Quick Ratio	3.89	5.49	4.23	3.81	1.29
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-64	-71	-14	-35
Operating Cash Flow to CapEx	-624.84%	-84.34%	-439.08%	0.00%	-23,610.87%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.03	0.03	0.02	0.00	0.00
Accounts Receivable Turnover	5.72	7.73	0.28	0.00	0.01
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.22	0.13	0.07	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	63.85	47.22	1,306.22	0.00	28,204.55
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	63.85	47.22	1,306.22	0.00	28,204.55
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	4.34	25	31	2.48	-11
Invested Capital Turnover	0.64	0.29	0.09	0.00	-0.01
Increase / (Decrease) in Invested Capital	0.00	21	6.34	-29	-13
Enterprise Value (EV)	0.00	-37	-6.53	-7.06	11
Market Capitalization	0.00	62	29	16	27
Book Value per Share	($3.78)	$2.90	$1.50	$5.59	$0.21
Tangible Book Value per Share	($3.78)	$2.90	$1.50	$5.59	$0.21
Total Capital	60	127	67	51	5.59
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00
Net Debt	-56	-99	-36	-48	-16
Capital Expenditures (CapEx)	5.54	41	12	-0.03	0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-10	-14	23	-2.46	-7.12
Debt-free Net Working Capital (DFNWC)	46	85	59	46	9.30
Net Working Capital (NWC)	46	85	59	46	9.30
Net Nonoperating Expense (NNE)	27	15	6.15	10	13
Net Nonoperating Obligations (NNO)	-56	-102	-36	-48	-16
Total Depreciation and Amortization (D&A)	3.01	3.56	4.36	5.85	3.64
Debt-free, Cash-free Net Working Capital to Revenue	-376.10%	-327.51%	882.55%	0.00%	-32,363.64%
Debt-free Net Working Capital to Revenue	1,653.39%	1,972.14%	2,285.36%	0.00%	42,272.73%
Net Working Capital to Revenue	1,653.39%	1,972.14%	2,285.36%	0.00%	42,272.73%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($22.30)	($16.00)	($12.03)	($2.73)
Adjusted Weighted Average Basic Shares Outstanding	0.00	2.61M	4.44M	4.60M	22.48M
Adjusted Diluted Earnings per Share	$0.00	($22.30)	($16.00)	($12.03)	($2.73)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	2.61M	4.44M	4.60M	22.48M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	4.42M	4.58M	26.00M	31.14M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-43	-47	-43	-45
Normalized NOPAT Margin	-1,024.88%	-1,013.97%	-1,824.89%	0.00%	-202,767.73%
Pre Tax Income Margin	-2,002.79%	-1,158.77%	-3,256.77%	0.00%	-280,131.82%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-0.43%	-4.02%

This table displays calculated financial ratios and metrics derived from Senti Biosciences' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	44,545,186.00	44,545,186.00	45,755,021.00	45,755,021.00	4,578,979.00	-	26,004,366.00	26,081,139.00	26,160,206.00	26,290,838.00	31,144,497.00
DEI Adjusted Shares Outstanding	4,454,519.00	4,454,519.00	4,575,502.00	4,575,502.00	4,578,979.00	-	26,004,366.00	26,081,139.00	26,160,206.00	26,290,838.00	31,144,497.00
DEI Earnings Per Adjusted Shares Outstanding	-3.35	-4.20	-2.65	-2.45	-6.30	-	-0.54	-0.56	-0.69	-0.55	-0.14
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-80.86%	0.00%	-100.00%	-100.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-156.99%	-40.66%	21.28%	26.35%	20.93%	103.50%	-16.77%	-34.59%	38.05%	-9,793.71%	72.74%
EBIT Growth	-150.58%	-45.58%	16.57%	23.96%	22.00%	95.60%	-14.98%	-31.16%	36.96%	-1,758.31%	69.69%
NOPAT Growth	-197.50%	-35.43%	-8.93%	12.06%	65.32%	13.54%	-0.59%	-25.77%	-11.39%	-15.27%	71.85%
Net Income Growth	10.32%	-2.78%	35.31%	40.08%	-93.43%	96.74%	-16.52%	-31.51%	37.21%	-2,271.64%	70.09%
EPS Growth	10.32%	-2.78%	35.31%	40.08%	-87.80%	96.92%	46.79%	77.14%	89.07%	-392.31%	90.07%
Operating Cash Flow Growth	-51.73%	21.86%	28.35%	38.98%	48.85%	-91.90%	-20.27%	-56.66%	-20.09%	49.09%	46.75%
Free Cash Flow Firm Growth	-126.13%	0.00%	-104.37%	100.36%	156.18%	189.74%	323.06%	10,783.20%	-108.01%	-98.49%	-57.26%
Invested Capital Growth	72.21%	25.47%	-10.66%	-25.07%	-87.35%	-92.07%	-87.47%	-89.13%	-174.47%	-537.09%	-257.01%
Revenue Q/Q Growth	-63.93%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-27.27%
EBITDA Q/Q Growth	-149.77%	50.31%	35.05%	8.64%	-168.15%	102.24%	-9,456.64%	-3.75%	-23.42%	20.28%	73.68%
EBIT Q/Q Growth	-147.26%	48.61%	34.91%	8.06%	-153.66%	97.10%	-1,701.76%	-3.43%	-21.92%	19.34%	70.61%
NOPAT Q/Q Growth	-188.89%	57.38%	12.82%	18.07%	-13.92%	-6.26%	-1.42%	-2.45%	-0.89%	-9.96%	75.23%
Net Income Q/Q Growth	20.19%	-25.42%	35.29%	7.50%	-157.66%	97.89%	-2,213.44%	-4.40%	-23.03%	20.19%	70.82%
EPS Q/Q Growth	20.19%	-25.42%	35.29%	7.50%	-157.55%	97.94%	-984.62%	60.28%	-23.21%	7.25%	78.13%
Operating Cash Flow Q/Q Growth	-12.46%	54.24%	-66.01%	28.57%	5.74%	-71.68%	-4.04%	6.95%	27.74%	27.22%	-8.81%
Free Cash Flow Firm Q/Q Growth	-44.51%	60.40%	61.15%	101.64%	22,162.92%	-36.74%	-3.44%	-19.97%	-116.38%	111.96%	2,627.75%
Invested Capital Q/Q Growth	15.79%	-28.61%	3.65%	-12.55%	-80.45%	-55.23%	63.72%	-24.18%	-234.01%	-162.76%	41.19%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%
EBITDA Margin	-10,502.96%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-63,009.09%	-22,800.00%
Operating Margin	-12,981.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-84,709.09%	-28,850.00%
EBIT Margin	-11,005.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-67,068.18%	-27,100.00%
Profit (Net Income) Margin	-4,415.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-65,759.09%	-26,381.25%
Tax Burden Percent	40.76%	100.14%	100.00%	100.00%	100.00%	100.00%	101.44%	100.00%	100.00%	98.70%	99.67%
Interest Burden Percent	98.43%	97.77%	97.34%	97.94%	99.48%	72.53%	97.25%	98.20%	99.09%	99.34%	97.67%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-688.31%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-708.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	489.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-199.03%	0.00%	0.00%	0.00%	-143.33%	-89.73%	-116.63%	-169.54%	-394.62%	-218.08%	-255.03%
Cash Return on Invested Capital (CROIC)	0.00%	-253.91%	-180.69%	-166.71%	-25.52%	-82.92%	-79.50%	-127.27%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-179.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-19.80%	-17.02%
Return on Assets (ROA)	-72.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-19.41%	-16.57%
Return on Common Equity (ROCE)	-199.03%	0.00%	0.00%	0.00%	-143.33%	-70.58%	-116.63%	-169.54%	-394.62%	-120.91%	-255.03%
Return on Equity Simple (ROE_SIMPLE)	-85.07%	0.00%	-114.89%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-31	-13	-11	-9.35	-11	-11	-11	-12	-12	-13	-3.23
NOPAT Margin	-9,086.75%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-59,296.36%	-20,195.00%
Net Nonoperating Expense Percent (NNEP)	20.49%	-8.15%	-1.40%	-4.91%	-73.38%	25.50%	-9.16%	-15.90%	-55.17%	-4.40%	-4.63%
Return On Investment Capital (ROIC_SIMPLE)	-	-19.56%	-20.34%	-21.17%	-66.51%	-44.12%	-30.32%	-47.70%	-146.09%	-233.41%	-125.97%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	2,790.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	26,572.73%	38,956.25%
R&D to Revenue	2,689.94%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	35,272.73%	33,006.25%
Operating Expenses to Revenue	13,081.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	84,809.09%	28,950.00%
Earnings before Interest and Taxes (EBIT)	-37	-19	-12	-11	-29	-0.84	-14	-15	-18	-15	-4.34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-36	-18	-11	-10	-28	0.62	-13	-14	-17	-14	-3.65
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.22	0.44	0.31	0.29	0.65	0.63	2.31	2.23	4.54	4.89	9.86
Price to Tangible Book Value (P/TBV)	0.22	0.44	0.31	0.29	0.65	0.63	2.31	2.23	4.54	4.89	9.86
Price to Revenue (P/Rev)	7.02	11.48	13.53	37.36	0.00	0.00	0.00	0.00	0.00	1,242.84	665.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	13.21	10.88	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	496.48	430.38
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.69	-0.71	-0.59	-0.53	-0.50	-0.71	-0.61	-0.54	-0.94	-1.15	-1.06
Leverage Ratio	1.44	1.55	1.57	1.63	1.92	1.85	1.97	2.26	4.58	2.65	2.99
Compound Leverage Factor	1.42	1.51	1.52	1.59	1.91	1.34	1.91	2.22	4.54	2.63	2.92
Debt to Total Capital	0.03%	0.00%	0.00%	0.05%	0.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.05%	0.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	49.47%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.97%	100.00%	100.00%	99.95%	99.88%	50.53%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.51	0.00	0.00	0.21	0.15	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.64	0.00	0.00	0.25	0.24	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-2.46	-2.45	-3.14	-4.08	-8.53	-3.51	-4.17	-6.23	-9.65	-10.17	-13.21
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	21.34%	0.00%	0.00%	0.00%	44.56%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.81	5.62	5.79	4.89	1.92	4.49	4.22	3.26	1.51	1.67	1.04
Quick Ratio	5.74	4.23	4.33	3.81	1.29	3.81	3.36	2.53	1.16	1.29	0.68
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-49	-19	-7.55	0.12	28	17	17	13	-2.21	0.26	7.20
Operating Cash Flow to CapEx	-827.72%	0.00%	-77,880.00%	0.00%	0.00%	-122,763.64%	0.00%	-6,669.90%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.02	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.27	0.28	0.14	0.04	0.00	0.00	0.00	0.00	0.00	0.01	0.03
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.07	0.07	0.03	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	1,356.45	1,306.22	2,678.67	10,383.06	0.00	0.00	0.00	0.00	0.00	28,204.55	14,326.25
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	1,356.45	1,306.22	2,678.67	10,383.06	0.00	0.00	0.00	0.00	0.00	28,204.55	14,326.25
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	44	31	32	28	5.54	2.48	4.06	3.08	-4.12	-11	-6.37
Invested Capital Turnover	0.08	0.09	0.04	0.01	0.00	0.00	0.00	0.00	0.00	-0.01	-0.03
Increase / (Decrease) in Invested Capital	18	6.34	-3.86	-9.47	-38	-29	-28	-25	-9.66	-13	-10
Enterprise Value (EV)	-21	-6.53	-6.47	-3.21	-0.11	-7.06	54	33	25	11	16
Market Capitalization	18	29	17	13	10	16	87	55	37	27	25
Book Value per Share	$1.86	$1.50	$1.23	$0.96	$3.49	$5.59	$1.46	$0.95	$0.31	$0.21	$0.08
Tangible Book Value per Share	$1.86	$1.50	$1.23	$0.96	$3.49	$5.59	$1.46	$0.95	$0.31	$0.21	$0.08
Total Capital	83	67	56	44	16	51	38	25	8.12	5.59	2.57
Total Debt	0.03	0.00	0.00	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-39	-36	-24	-16	-10	-48	-34	-22	-12	-16	-8.94
Capital Expenditures (CapEx)	1.86	-0.10	0.02	0.00	-0.06	0.01	0.00	0.20	0.00	0.00	-0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	29	23	22	19	-2.14	-2.46	0.69	0.96	-6.11	-7.12	-8.41
Debt-free Net Working Capital (DFNWC)	69	59	46	35	8.34	46	34	23	6.13	9.30	0.52
Net Working Capital (NWC)	69	59	46	35	8.32	46	34	23	6.13	9.30	0.52
Net Nonoperating Expense (NNE)	-16	5.63	0.70	1.85	18	-11	2.63	2.97	6.26	1.42	0.99
Net Nonoperating Obligations (NNO)	-39	-36	-24	-16	-10	-48	-34	-22	-12	-16	-8.94
Total Depreciation and Amortization (D&A)	1.70	1.47	0.98	0.97	0.95	1.46	0.93	0.91	0.90	0.89	0.69
Debt-free, Cash-free Net Working Capital to Revenue	1,124.97%	882.55%	1,751.69%	5,748.82%	0.00%	0.00%	0.00%	0.00%	0.00%	-32,363.64%	-22,139.47%
Debt-free Net Working Capital to Revenue	2,630.51%	2,285.36%	3,612.31%	10,441.12%	0.00%	0.00%	0.00%	0.00%	0.00%	42,272.73%	1,373.68%
Net Working Capital to Revenue	2,630.51%	2,285.36%	3,612.31%	10,435.21%	0.00%	0.00%	0.00%	0.00%	0.00%	42,272.73%	1,373.68%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.40)	($42.20)	($2.60)	($2.45)	($6.31)	($0.13)	($1.41)	($0.56)	($0.69)	($0.64)	($0.14)
Adjusted Weighted Average Basic Shares Outstanding	4.45M	443.71K	4.57M	4.57M	4.58M	4.60M	10.01M	26.08M	26.23M	22.48M	30.97M
Adjusted Diluted Earnings per Share	($3.40)	($42.20)	($2.60)	($2.45)	($6.31)	($0.13)	($1.41)	($0.56)	($0.69)	($0.64)	($0.14)
Adjusted Weighted Average Diluted Shares Outstanding	4.45M	443.71K	4.57M	4.57M	4.58M	4.60M	10.01M	26.08M	26.23M	22.48M	30.97M
Adjusted Basic & Diluted Earnings per Share	$0.00	($42.20)	$0.00	$0.00	$0.00	($0.13)	$0.00	$0.00	$0.00	($0.64)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	4.45M	4.58M	4.58M	4.58M	4.59M	26.00M	26.08M	26.16M	26.29M	31.14M	31.14M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-13	-11	-9.35	-11	-11	-11	-12	-12	-13	-3.23
Normalized NOPAT Margin	-3,766.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-59,296.36%	-20,195.00%
Pre Tax Income Margin	-10,832.84%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-66,627.27%	-26,468.75%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-0.43%	-3.93%	-4.61%	-5.67%	-4.02%	-1.06%

Financials Breakdown Chart

Senti Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Senti Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Senti Biosciences' net income were at -$61.44 million at the end of 2025, a 16.4% increase from 2024, and a 11.1% increase since 2021. View Senti Biosciences' forecast to see where analysts expect Senti Biosciences to go next.

Senti Biosciences' total operating income in 2025 was -$68.78 million, based on the following breakdown:

Total Gross Profit: $22 thousand
Total Operating Expenses: $68.80 million

Over the last 4 years, Senti Biosciences' total revenue changed from $2.76 million in 2021 to $22 thousand in 2025, a change of -99.2%.

Senti Biosciences' total liabilities were at $45.63 million at the end of 2025, a 3.1% decrease from 2024, and a 25.6% increase since 2021.

In the past 4 years, Senti Biosciences' cash and equivalents has ranged from $16.42 million in 2025 to $57.62 million in 2022, and is currently $16.42 million as of their latest financial filing in 2025.

Over the last 4 years, Senti Biosciences' book value per share changed from -3.78 in 2021 to 0.21 in 2025, a change of -105.6%.

Related Companies

Financial statements for NASDAQ:SNTI last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Senti Biosciences (SNTI) Financials

Financials Breakdown Chart

Senti Biosciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Senti Biosciences (SNTI) Financials

Annual Income Statements for Senti Biosciences

Quarterly Income Statements for Senti Biosciences

Annual Cash Flow Statements for Senti Biosciences

Quarterly Cash Flow Statements for Senti Biosciences

Annual Balance Sheets for Senti Biosciences

Quarterly Balance Sheets for Senti Biosciences

Annual Metrics And Ratios for Senti Biosciences

Quarterly Metrics And Ratios for Senti Biosciences

Financials Breakdown Chart

Senti Biosciences Financials - Frequently Asked Questions

When does Senti Biosciences' fiscal year end?

How has Senti Biosciences' net income changed over the last 4 years?

What is Senti Biosciences' operating income?

How has Senti Biosciences' revenue changed over the last 4 years?

How much debt does Senti Biosciences have?

How much cash does Senti Biosciences have?

How has Senti Biosciences' book value per share changed over the last 4 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools